Sight Sciences (SGHT) Set to Announce Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. The business had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $7.75 on Tuesday. The business’s 50-day moving average price is $6.75 and its two-hundred day moving average price is $5.61. Sight Sciences has a twelve month low of $1.04 and a twelve month high of $9.31. The stock has a market cap of $385.64 million, a P/E ratio of -6.92 and a beta of 2.75. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31.

Insider Transactions at Sight Sciences

In other news, insider Jeremy B. Hayden sold 5,055 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $6.21, for a total value of $31,391.55. Following the completion of the sale, the insider now directly owns 163,565 shares of the company’s stock, valued at approximately $1,015,738.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Alison Bauerlein sold 13,066 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $5.42, for a total transaction of $70,817.72. Following the completion of the sale, the chief financial officer now directly owns 413,182 shares of the company’s stock, valued at approximately $2,239,446.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeremy B. Hayden sold 5,055 shares of Sight Sciences stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $6.21, for a total value of $31,391.55. Following the sale, the insider now directly owns 163,565 shares of the company’s stock, valued at $1,015,738.65. The disclosure for this sale can be found here. Insiders sold a total of 47,840 shares of company stock valued at $290,061 over the last 90 days. Company insiders own 28.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SGHT. Piper Sandler restated a “neutral” rating and set a $6.00 price target (up from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. Morgan Stanley raised their price target on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Citigroup raised their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Sight Sciences currently has a consensus rating of “Hold” and an average target price of $5.70.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.